The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | Increasing diversity in clinical trials for lung cancer
Julie Barta, MD, Thomas Jefferson University, Philadelphia, PA, comments on the need to enhance diversity in lung cancer clinical studies. Multiple strategies such as community engagement, developing infrastructure in underserved communities, and changing the inclusion criteria are necessary to ensure fair racial and ethnic representation. In the CASCADE-LUNG (NCT05306288) study, a diverse cohort ensured that the blood-based assay that was assessed will be effective in the population that it will be used in. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
